Lacosamide
Material: | 1 ml serum. Dried capillary blood Mitra collection system (10 µl) Blood collection just before next dose. |
Methods: | Flüssigkeitschromatographie-Massenspektrometrie (LC-MS/MS) → LC-Tandem-Massenspektrometrie |
Indication | (Therapeutic) drug monitoring |
Therapeutic range | 1,0 mg/l – 10,0 mg/l Alert level: > 20 mg/l |
Please note | Caution is to be applied in case of simultaneous therapy with lacosamide and strong inhibitors of the enzymes CYP2C9 (i.e. fluconazole) and CYP3A4 (i.e. itraconazole, ketoconazole, ritonavir, clarithromycin), as these can lead to an increased lacosamide level. Extreme overdose can be expected to lead to toxic side effects (dizziness, gastroduodenal problems such as nausea and vomiting). |
Accredited | ja |
More Results for the letter L
- Lipometabolism diagnostics (LIPID)
- fat metabolism diagnostics
- Lipoprotein (a) = Lp (a) (LPA)
- Listeriosis (KLIST, LISMON)
- Listeria monocytogenes
- Lithium (LI)
- LKM autoantibodies (LKM)
- autoantibodies to liver and kidney microsomes
- LMA autoantibodies (LMA)
- Liver membrane antigen autoantibodies
- Lorazepam (LORA)
- Lormetazepam (LORM)
- LSD (LSDU)
- Lysergic acid diethylamide
- Lupus coagulant activity (LUPAK)
- Lymphocyte differentiation (LYMPD, LYMPDG, TREG, TAKT)
- Immune status
- Lysozyme (LYSOZ)